Bharat Immunologicals & Biologicals Corporation (BSE: BIBCL) is loss-making over the last 12 months, losing ₹18 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹8.51, 62% below its 52-week high. Debt is 0.94× equity. It is a small-cap company with a market cap of ₹37 Cr, ranked 15th of 20 Biotechnology companies by market cap; the shares fell 57% over the past year.
- ₹8.66
- ₹8.96
- ₹8.11
- ₹8.83
- 63.2K
Health check
- ReturnsBehind
−56.6% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- Growthn/a
Not enough yearly results to measure.
- ProfitabilityNegative
ROCE -16.2% vs peer median 16.7%.
- Balance sheetStretched
Debt 0.94× equity, operating profit doesn’t cover interest, Piotroski 3 of 9.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹37 Cr
- Small cap
- P/E
- n/a
- Industry 49.1
- Price to book
- 0.47
- Peers 4.68
- Dividend yield
- 0.00%
- ROE
- −21.0%
- Peers 14.3%
- ROCE
- −16.2%
- Peers 16.7%
- Debt to equity
- 0.94
- Debt ₹74 Cr
- EPS (TTM)
- −₹2.26
- OPM (TTM)
- −2888.4%
- Net margin −241.6%
- Sales growth
- −99.4%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 4.80
- EV/EBITDA −5.1
Strengths and risks
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −21.0%.
- Quarterly sales down 99.4% on a year ago.
- 62% below its 52-week high.
- Interest coverage of only −2.3×.
About Bharat Immunologicals & Biologicals Corporation
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, engages in the manufacture and sale of pharmaceutical products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, and BIB sweet tablets. The company was incorporated in 1989 and is based in Bulandshahr, India.
- Headquarters
- Bulandshahr
- Sector
- Healthcare
- ISIN
- INE994B01014
- Website
- bibcol.sciencecentral.in
Price range
- Avg volume (3M)
- 56.3K
- 1-year return
- minus 56.6%
- From 52-week high
- minus 62.4%
Peers · Biotechnology
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon | 365.10 | plus 0.86% | 59,794 | 122.5 | 1.73 | 2.8% | 1.0% | 19.4% | 15.3% | −5.9% | 0.14% | minus 4.9% |
| ANTHEMAnthem Biosciences | 915.55 | plus 0.22% | 51,594 | 84.6 | 15.74 | 26.8% | 20.4% | 41.4% | 26.2% | 15.4% | 0.22% | plus 30.1% |
| ONESOURCEOnesource Specialty Pharma | 1,599.80 | plus 1.13% | 18,346 | – | 3.10 | 0.3% | 0.0% | 23.5% | 232.3% | – | 0.00% | minus 13.7% |
| CONCORDBIOConcord Biotech | 632.60 | minus 5.96% | 13,236 | 47.4 | 6.48 | 16.7% | 14.3% | 34.5% | 8.0% | 2.8% | 0.60% | minus 7.5% |
| BLUEJETBlue Jet Healthcare | 553.80 | minus 3.91% | 9,607 | 34.5 | 4.52 | 24.0% | 19.9% | 31.4% | 9.4% | 15.7% | 0.22% | minus 5.0% |
| SUPRIYASupriya Lifescience | 695.80 | minus 19.99% | 5,600 | 28.2 | 4.68 | 22.3% | 19.1% | 21.4% | 21.2% | 32.5% | 0.14% | plus 9.2% |
| ZOTAZota Health Care | 1,231.10 | plus 1.01% | 4,264 | – | 6.82 | −7.3% | −24.1% | 0.1% | 56.7% | – | 0.08% | minus 21.9% |
| BIBCLBharat Immunologicals & Biologicals Corporation | 8.51 | minus 3.62% | 37 | – | 0.47 | −16.2% | −21.0% | −2888.4% | – | – | 0.00% | minus 56.6% |
| Median of 7 peers | – | 0.22% | 13,236 | 47.4 | 4.68 | 16.7% | 14.3% | 23.5% | 21.2% | 15.4% | 0.14% | −5.0% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- ROE
- −21.0%
| ₹ Cr | Mar 2022 | Mar 2023 |
|---|---|---|
| 78.4 | 44.6 | |
| 83 | 60.4 | |
| −4.6 | −15.8 | |
| −5.9% | −35.4% | |
| 0.6 | 0.3 | |
| 5.1 | 7 | |
| 0.2 | 0.2 | |
| −0.3 | 0.4 | |
| −9.7 | −22.3 | |
| 9.6% | 25.3% | |
| −8.8 | −16.6 | |
| -2.03 | -3.85 |
Forecast
Balance sheet
| ₹ Cr | Mar 2022 | Mar 2023 |
|---|---|---|
| 43.2 | 43.2 | |
| 62.2 | 45 | |
| 77.9 | 70.2 | |
| 29.5 | 30.2 | |
| 213 | 189 | |
| 116 | 116 | |
| 31.9 | 31.4 | |
| 4.6 | 1.3 | |
| 60.2 | 40.2 | |
| 213 | 189 |
Cash flow
| ₹ Cr | Mar 2022 | Mar 2023 |
|---|---|---|
| −42.1 | 10.9 | |
| 0.5 | 0.5 | |
| 45 | −14.7 | |
| 3.4 | −3.4 | |
| −42.1 | 10.9 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.